Download PDF
Diabetes aktuell 2021; 19(02): 76-80
DOI: 10.1055/a-1452-1412
Schwerpunkt

Autoimmunerkrankung Typ-1-Diabetes

Forschungsansätze und Entwicklung zukünftiger Interventionsstrategien
Martin G. Scherm
1   Institute of Diabetes Research, Group Immune Tolerance in Type 1 Diabetes, Helmholtz Diabetes Center, Helmholtz Zentrum München
2   Deutsches Zentrum für Diabetesforschung (DZD), München
,
Carolin Daniel
1   Institute of Diabetes Research, Group Immune Tolerance in Type 1 Diabetes, Helmholtz Diabetes Center, Helmholtz Zentrum München
2   Deutsches Zentrum für Diabetesforschung (DZD), München
3   Division of Clinical Pharmacology, Department of Medicine IV, Ludwig-Maximilians-Universität München
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Die umfassende Erforschung der Immunologie des Typ-1-Diabetes kann entscheidend zu unserem Verständnis der Krankheit beitragen. Hierbei ist insbesondere auch die Identifizierung der zugrundeliegenden Signalwege, die zur fehlerhaften Immuntoleranz sowie der Aktivierung und dem Fortschreiten der Inselautoimmunität beitragen, von entscheidender Bedeutung für die Entwicklung zukünftiger Interventionsstrategien, um die Entstehung von Typ-1-Diabetes zu verlangsamen oder sogar ganz zu verhindern [1]. So bieten kürzlich identifizierte miRNAs, die zur Entstehung von Inselautoimmunität beitragen, einen vielversprechenden Ansatz, um Treg-vermittelte Toleranzdefekte mittels gezielter miRNA-Modulation zu reduzieren.



Publication History

Article published online:
29 April 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Ziegler AG, Bonifacio E. Shortening the paths to type 1 diabetes mellitus prevention. Nat Rev Endocrinol 2021; 17: 73-74
    CrossrefPubMedSearch in Google Scholar
  • 2 Patterson CC, Dahlquist GG, Gyürüs E. et al Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study. Lancet 2009; 373: 2027-2033
    CrossrefPubMedSearch in Google Scholar
  • 3 Bonifacio E, Hummel M, Walter M. et al IDDM1 and multiple family history of type 1 diabetes combine to identify neonates at high risk for type 1 diabetes. Diabetes Care 2004; 27: 2695-7000
    CrossrefPubMedSearch in Google Scholar
  • 4 Winkler C, Jolink M, Knopff A. et al Age, HLA, and Sex Define a Marked Risk of Organ-Specific Autoimmunity in First-Degree Relatives of Patients With Type 1 Diabetes. Diabetes Care 2019; 42: 1684-1691
    CrossrefPubMedSearch in Google Scholar
  • 5 Hippich M, Beyerlein A, Hagopian WA. et al Genetic Contribution to the Divergence in Type 1 Diabetes Risk Between Children From the General Population and Children From Affected Families. Diabetes 2019; 68: 847-857
    CrossrefPubMedSearch in Google Scholar
  • 6 Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1 diabetes. Immunity 2010; 32: 468-478
    CrossrefPubMedSearch in Google Scholar
  • 7 Rodriguez-Calvo T, Richardson SJ, Pugliese A. Pancreas Pathology During the Natural History of Type 1 Diabetes. Curr Diab Rep 2018; 18: 124
    CrossrefPubMedSearch in Google Scholar
  • 8 Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26: 832-836
    CrossrefPubMedSearch in Google Scholar
  • 9 Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 04: 330-336
    CrossrefPubMedSearch in Google Scholar
  • 10 Serr I, Fürst RW, Ott VB. et al miRNA92a targets KLF2 and the phosphatase PTEN signaling to promote human T follicular helper precursors in T1D islet autoimmunity. Proc Natl Acad Sci U S A 2016; 113: E6659-E6668
    CrossrefPubMedSearch in Google Scholar
  • 11 Serr I, Scherm MG, Zahm AM. et al A miRNA181a/NFAT5 axis links impaired T cell tolerance induction with autoimmune type 1 diabetes. Sci Transl Med 2018; 10: eaag1782
    CrossrefPubMedSearch in Google Scholar
  • 12 Scherm MG, Serr I, Zahm AM. et al miRNA142-3p targets Tet2 and impairs Treg differentiation and stability in models of type 1 diabetes. Nat Commun 2019; 10: 5697
    CrossrefPubMedSearch in Google Scholar
  • 13 Ziegler AG, Kick K, Bonifacio E. et al Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA 2020; 323: 339-351
    CrossrefPubMedSearch in Google Scholar
  • 14 Ziegler AG, Rewers M, Simell O. et al Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309: 2473-2479
    CrossrefPubMedSearch in Google Scholar
  • 15 Serr I, Fürst RW, Achenbach P. et al Type 1 diabetes vaccine candidates promote human Foxp3(+)Treg induction in humanized mice. Nat Commun 2016; 07: 10991
    CrossrefPubMedSearch in Google Scholar
  • 16 Polansky JK, Kretschmer K, Freyer J. et al DNA methylation controls Foxp3 gene expression. Eur J Immunol 2008; 38: 1654-1663
    CrossrefPubMedSearch in Google Scholar
  • 17 Scherm MG, Daniel C. miRNA Regulation of T Cells in Islet Autoimmunity and Type 1 Diabetes. Curr Diab Rep 2020; 20: 41
    CrossrefPubMedSearch in Google Scholar
  • 18 Scherm MG, Serr I, Kaestner KH, Daniel C. The role of T cell miRNAs for regulatory T cell induction in islet autoimmunity. Mol Metab 2019; 27 S(Suppl) S122-S128
    CrossrefPubMedSearch in Google Scholar
  • 19 Scherm MG, Daniel C. miRNA-Mediated Immune Regulation in Islet Autoimmunity and Type 1 Diabetes. Front Endocrinol (Lausanne) 2020; 11: 606322
    CrossrefPubMedSearch in Google Scholar